Phaseline

Targets › IRS1

IRS1 (Insulin receptor substrate 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2030.

Signaling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R. Plays therefore an important role in development, growth, glucose homeostasis as well as lipid metabolism. Upon phosphorylation by the insulin receptor, functions as a signaling scaffold that propagates insulin action through…. (UniProt, P35568)

Open in Phaseline: the race on IRS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Colorado, DenverNT219
IRS1/2 and STAT3 inhibitor
IRS1, IRS2, STAT3Phase 1Head and Neck CancerFeb 2030

Conditions

Head and Neck Cancer (1)

Modalities

small molecule (1)

Companies

University of Colorado, Denver (1)

Related targets

IRS2 (1) STAT3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.